Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/parp-inhibitors-for-the-treatment-and-prevention-of-breast-cancer-QaSXJKYWPu
References (40)
-
M. Rouleau, Anand Patel, M. Hendzel, S. Kaufmann, G. Poirier (2010)
PARP inhibition: PARP1 and beyondNature Reviews Cancer, 10
-
K. Hastak, E. Alli, J. Ford (2010)
Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.Cancer research, 70 20
-
V. Vogel, J. Costantino, D. Wickerham, W. Cronin, R. Cecchini, J. Atkins, T. Bevers, L. Fehrenbacher, E. Pajon, J. Wade, A. Robidoux, R. Margolese, J. James, S. Lippman, C. Runowicz, P. Ganz, S. Reis, W. McCaskill-Stevens, L. Ford, V. Jordan, N. Wolmark (2006)
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.JAMA, 295 23
-
S. Narod (2002)
Modifiers of risk of hereditary breast and ovarian cancerNature Reviews Cancer, 2
-
P. Fong, D. Boss, T. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, Peter Mortimer, H. Swaisland, A. Lau, M. O’Connor, A. Ashworth, J. Carmichael, S. Kaye, J. Schellens, J. Bono (2009)
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.The New England journal of medicine, 361 2
-
L. Carey, C. Perou, C. Livasy, L. Dressler, D. Cowan, K. Conway, G. Karaca, M. Troester, C. Tse, S. Edmiston, Sandra Deming, J. Geradts, M. Cheang, T. Nielsen, P. Moorman, H. Earp, R. Millikan (2006)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.JAMA, 295 21
-
This is the first report of clinical results from a phase II randomized trial with BSI-201 for treatment of sporadic triple-negative advanced breast cancer -
J. Jonkers, A. Berns (2002)
Conditional mouse models of sporadic cancerNature Reviews Cancer, 2
-
M. Spry, Timothy Scott, H. Pierce, J. D'Orazio (2007)
DNA repair pathways and hereditary cancer susceptibility syndromes.Frontiers in bioscience : a journal and virtual library, 12
-
T. Sørlie, R. Tibshirani, Joel Parker, T. Hastie, J. Marron, A. Nobel, Shibing Deng, H. Johnsen, Robert Pesich, S. Geisler, J. Demeter, C. Perou, P. Lønning, P. Brown, A. Børresen-Dale, D. Botstein (2003)
Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences of the United States of America, 100
-
Yuxin Li, P. Brown (2007)
Translational approaches for the prevention of estrogen receptor-negative breast cancerEuropean Journal of Cancer Prevention, 16
-
A. Hartman, J. Ford (2002)
BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repairNature Genetics, 32
-
K. Hastak, E. Alli, J. Ford (2010)
Synergistic chemosensitivity of triple-negative breast cancer cell lines to PARP inhibition, gemcitabine and cisplatin -
D. Weinstock, K. Nakanishi, Hildur Helgadottir, M. Jasin (2006)
Assaying double-strand break repair pathway choice in mammalian cells using a targeted endonuclease or the RAG recombinase.Methods in enzymology, 409
-
H. Willers, A. Taghian, Chen-Mei Luo, A. Treszezamsky, D. Sgroi, S. Powell (2009)
Utility of DNA Repair Protein Foci for the Detection of Putative BRCA1 Pathway Defects in Breast Cancer BiopsiesMolecular Cancer Research, 7
-
(2009)
first phase I dose escalation study of olaparib in patients with advanced refractory solid tumors with patient population enriched for BRCA1 and BRCA2 mutation carriers -
J. O'Shaughnessy, Cynthia Osborne, J. Pippen, M. Yoffe, Debra Patt, G. Monaghan, C. Rocha, V. Ossovskaya, B. Sherman, C. Bradley (2009)
Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
H. Saito, Y. Miki (2011)
[PARP inhibitors for cancer therapy].Gan to kagaku ryoho. Cancer & chemotherapy, 38 1
-
A. Tutt, Mark Robson, J. Garber, S. Domchek, M. Audeh, J. Weitzel, M. Friedlander, J. Carmichael (2009)
Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 18_suppl
-
A. Kurian, L. McClure, E. John, P. Horn‐Ross, J. Ford, C. Clarke (2009)
Second primary breast cancer occurrence according to hormone receptor status.Journal of the National Cancer Institute, 101 15
-
S. Narod, W. Foulkes (2004)
BRCA1 and BRCA2: 1994 and beyondNature Reviews Cancer, 4
-
B. Schneider, E. Winer, W. Foulkes, J. Garber, C. Perou, A. Richardson, G. Sledge, L. Carey (2008)
Triple-Negative Breast Cancer: Risk Factors to Potential TargetsClinical Cancer Research, 14
-
E. John, A. Miron, G. Gong, A. Phipps, Anna Felberg, Frederick Li, D. West, A. Whittemore (2007)
Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups.JAMA, 298 24
-
Susan Cleator, Susan Cleator, W. Heller, R. Coombes, R. Coombes (2007)
Triple-negative breast cancer: therapeutic options.The Lancet. Oncology, 8 3
-
E. John, A. Miron, G. Gong, A. Phipps, Anna Felberg, Frederick Li, D. West, A. Whittemore (2007)
Prevalence of Pathogenic BRCA 1 Mutation Carriers in 5 US Racial / Ethnic Groups -
R. Dent, G. Lindeman, M. Clemons, H. Wildiers, A. Chan, N. Mccarthy, C. Singer, E. Lowe, K. Kemsley, J. Carmichael (2010)
Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.Journal of Clinical Oncology, 28
-
B. Rowe, P. Glazer (2010)
Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanismsBreast Cancer Research : BCR, 12
-
B. Durkacz, O. Omidiji, D. Gray, S. Shall (1980)
(ADP-ribose)n participates in DNA excision repairNature, 283
-
H. Farmer, N. Mccabe, C. Lord, A. Tutt, Damian Johnson, T. Richardson, M. Santarosa, Krystyna Dillon, I. Hickson, C. Knights, N. Martin, S. Jackson, G. Smith, A. Ashworth (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 434
-
A. Simons, N. Dafni, I. Dotan, Y. Oron, D. Canaani (2001)
Establishment of a chemical synthetic lethality screen in cultured human cells.Genome research, 11 2
-
E. Alli, Vandana Sharma, Preethi Sunderesakumar, J. Ford (2009)
Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.Cancer research, 69 8
-
K. Metcalfe, D. Birenbaum-Carmeli, J. Lubiński, J. Gronwald, H. Lynch, P. Møller, P. Ghadirian, W. Foulkes, J. Klijn, E. Friedman, C. Kim-sing, P. Ainsworth, B. Rosen, S. Domchek, T. Wagner, N. Tung, S. Manoukian, F. Couch, P. Sun, S. Narod (2008)
International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriersInternational Journal of Cancer, 122
-
H. Bryant, N. Schultz, H. Thomas, Kayan Parker, Dan Flower, Elena Lopez, S. Kyle, M. Meuth, N. Curtin, T. Helleday (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 434
-
A. Whittemore, G. Gong, E. John, V. McGuire, Frederick Li, K. Ostrow, R. Dicioccio, Anna Felberg, D. West (2004)
Prevalence of BRCA 1 Mutation Carriers among U . S . Non-Hispanic Whites -
W. Bonner, C. Redon, J. Dickey, A. Nakamura, O. Sedelnikova, S. Solier, Y. Pommier (2008)
γH2AX and cancerNature Reviews Cancer, 8
-
J. O’Shaughnessy, C. Osborne, J. Pippen, D. Patt, C. Rocha, V. Ossovskaya, B. Sherman, C. Bradley (2009)
Final Results of a Randomized Phase II Study Demonstrating Efficacy and Safety of BSI-201, a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor, in Combination with Gemcitabine/Carboplatin (G/C) in Metastatic Triple Negative Breast Cancer (TNBC).Cancer Research, 69
-
A. Mendes-Pereira, S. Martin, R. Brough, Afshan Mccarthy, J. Taylor, Jung‐Sik Kim, T. Waldman, C. Lord, A. Ashworth (2009)
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitorsEMBO Molecular Medicine, 1
-
A. Whittemore, G. Gong, E. John, V. McGuire, Frederick Li, K. Ostrow, R. Dicioccio, Anna Felberg, D. West (2004)
Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 13 12
-
B. Fisher, J. Costantino, D. Wickerham, C. Redmond, M. Kavanah, W. Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, M. Daly, S. Wieand, E. Tan-chiu, L. Ford, N. Wolmark (1999)
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.Journal of the National Cancer Institute, 90 18
-
C. Banuelos, J. Banáth, Joo-Young Kim, C. Aquino-Parsons, P. Olive (2009)
γH2AX Expression in Tumors Exposed to Cisplatin and Fractionated IrradiationClinical Cancer Research, 15
- Publisher
- Springer Journals
- Copyright
- Copyright © 2010 by Springer Science+Business Media, LLC
- Subject
- Medicine & Public Health; Surgical Oncology; Internal Medicine; Oncology
- ISSN
- 1943-4588
- eISSN
- 1943-4596
- DOI
- 10.1007/s12609-010-0026-0
- Publisher site
- See Article on Publisher Site
Abstract
Poly (ADP-ribose) polymerase (PARP) inhibitors, a novel class of drugs that target tumors with DNA repair defects, have received tremendous enthusiasm. Early preclinical studies identified BRCA1 and BRCA2 tumors to be highly sensitive to PARP inhibitors as a result of homologous recombination defect. Based on this premise, PARP inhibitors have been tested in early phase clinical trials as a single agent in BRCA1 or BRCA2 mutation carriers and in combination with chemotherapy in triple-negative breast cancer patients. For high-risk populations, use of PARP inhibition as a prevention agent has been postulated, but no robust preclinical or clinical studies exist yet. We review the preclinical and clinical studies in treatment of breast cancer and rationale for use of PARP inhibitors as a prevention agent for high-risk populations. Of significance, PARP inhibitors vary significantly in mechanism of action, dosing intervals, and toxicities, which are highlighted in this review.
Journal
Current Breast Cancer Reports – Springer Journals
Published: Sep 26, 2010